Organon (OGN) announced it has expanded its agreement with Eli Lilly (LLY) to become the sole distributor and promoter for the migraine medicine Emgality in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. This expanded partnership builds on Organon’s role as sole distributor and promoter of Emgality in Europe since February. Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. Lilly will remain the marketing authorization holder and will manufacture the product for sale. Total consideration to be paid to Lilly for the expansion of territory includes an upfront payment of $22.5M as well as sales-based milestone payments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon narrows FY24 revenue view to $6.25B-$6.45B from $6.2B-$6.5B
- Organon reports Q2 adjusted EPS $1.12, consensus $1.08
- Organon’s Latest Quarterly Financial Results Presentation
- 3 Cheap Stocks Yielding Over 5% with “Perfect 10” Smart Scores
- Organon (NYSE:OGN): Underappreciated Healthcare Stock with a 5.4% Dividend Yield